Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All News Releases
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Hamburger menu
    • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • Create a Free Account
      • ALL CONTACT INFO
      • Contact Us


        11AM ET Sunday – 8PM ET Friday

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Why PRWeb
    • Contact
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Nobias Therapeutics Announces Strategic Focus and New Leadership


      News provided by

      Nobias Therapeutics

      Nov 14, 2024, 07:00 ET

      Share this article

      Share this article


      Nobias Therapeutics
      Nobias Therapeutics

      Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, has announced its intent to focus its resources on its development programs following receipt of positive data from a multi-center, randomized, double blind, placebo-controlled Phase 2 clinical trial of its lead asset, NB-001.

      PHILADELPHIA, Nov. 14, 2024 /PRNewswire-PRWeb/ -- Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, has announced its intent to focus its resources on its development programs following receipt of positive data from a multi-center, randomized, double blind, placebo-controlled Phase 2 clinical trial of its lead asset, NB-001. NB-001 is a small-molecule metabotropic glutamate receptor (mGluR) modulator for the potential treatment of the neuropsychiatric symptoms associated with 22q11 deletion syndrome (22q11DS), the most common human microdeletion.

      Children living with 22q11DS, also known as DiGeorge syndrome, typically experience a distinctive mix of neuropsychiatric conditions that include elements of ADHD, anxiety, and autism. Currently, there are no population-specific approved therapies for these conditions, leaving many patients with inadequate treatment options and resulting in a significant burden for their parents and other caretakers. As an mGluR activator, NB-001 is uniquely positioned to help compensate for the disruption to neuronal signaling caused by this deletion—which is responsible for the often severe neuropsychiatric symptoms experienced by 22q11DS patients.

      After reviewing the positive data from the Phase 2 clinical trial, which demonstrate the safety and tolerability of NB-001 – and a clear efficacy signal – we believe this compound has the ability to change patient lives

      Post this

      "After reviewing the positive data from the Phase 2 clinical trial, which demonstrate the safety and tolerability of NB-001 – and a clear efficacy signal – we believe this compound has the ability to change patient lives," said Patrick Dougherty, CEO. "Following development of a disease-specific clinical global impression (CGI) assessment scale this summer, we are now focused on Q4 discussions with the FDA to clarify the regulatory path to advance NB-001 into a registrational study for 22q11DS."

      As part of this sharpened focus, Patrick Dougherty has been named CEO at Nobias Therapeutics. Dougherty, who had been consulting for Nobias since 2021, is a life sciences executive with more than 20 years of experience at the intersection of science and business across a range of leadership roles, including a decade at GSK in R&D strategy and business development, as part of the management team at WindMIL Therapeutics, and as an engagement manager at L.E.K. Consulting. Prior to joining Nobias, Dougherty established Beech Street Advisors, LLC, a biotech advisory practice supporting early-stage therapeutic companies by providing hands-on, functional leadership in business strategy, business development, and executive operations.

      "The entire Board is thrilled to have Patrick join Nobias in this capacity," said Brian Halak, Nobias co-founder, Chairman of the Nobias Board of Directors, and a Partner at Domain Associates and Medical Excellence Capital. "Following receipt of the impressive Phase 2 data, we immediately recognized Nobias' 22q program as a groundbreaking and critical asset deserving of our full commitment. NB-001 is going to bring better treatment options to children with 22q11DS, and holds significant expansion potential – for adults with 22q11DS, and more broadly, other patients living with comorbid psychiatric symptoms that may be driven by genetic disruptions to glutamatergic signaling."

      As a result of these changes, the company has also relocated the base of its operations to its office in the University City section of Philadelphia. This location provides access to local medical and scientific expertise and to the robust pool of late-stage development talent present in the Philadelphia pharma/biotech ecosystem.

      Visit the company's newly redeveloped website, http://www.nobiastx.com, to learn more.

      About Nobias Therapeutics
      Nobias Therapeutics is a clinical-stage company developing novel small molecule therapeutics for rare diseases. Our unique access to rich genomic and health datasets and strong relationships with pediatric academic medical centers across North America allow us to rapidly advance drug discovery for genetically-defined rare diseases, with an initial focus on pediatric indications, but expansion opportunities in adults and non-rare indications. To learn more, please visit http://www.nobiastx.com and follow Nobias Therapeutics on LinkedIn.

      Media Contact

      Nobias Therapeutics, Nobias Therapeutics, 315-463-2325, [email protected], www.nobiastx.com

      SOURCE Nobias Therapeutics

      Modal title

      Contact PRWeb

      • 11AM ET Sunday – 8PM ET Friday
      • Contact Us

      About PRWeb

      • About PRWeb
      • Partners
      • Partnership Programs
      • Editorial Guidelines
      • Resources

      Why PRWeb

      • Why PRWeb
      • How It Works
      • Who Uses It
      • Pricing

      Accounts

      • Create a Free Account
      • Log in
      • Contact Us

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Online Member Center
      • ProfNet
      Cision Distribution Helpline
      888-776-0942
      • Legal
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 Cision US Inc.